Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 20
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Molecules ; 26(21)2021 Oct 31.
Artigo em Inglês | MEDLINE | ID: mdl-34771012

RESUMO

Naringin is a kind of multi-source food additive which has been explored broadly for its various biological activities and therapeutic potential. In the present study, the protective effect and mechanism of naringin on dextran sulfate sodium (DSS)-induced ulcerative colitis (UC) in mice were investigated. The results showed that naringin significantly alleviated DSS-induced colitis symptoms, including disease activity index (DAI), colon length shortening, and colon pathological damage. The tissue and serum secretion of inflammatory cytokines, as well as the oxidative stress, were decreased accordingly upon naringin intervention. Naringin also decreased the proteins involved in inflammation and increased the expression of tight junction (TJ) proteins. Moreover, naringin increased the relative abundance of Firmicutes/Bacteroides and reduced the content of Proteobacteria to improve the intestinal flora disorder caused by DSS, which promotes the intestinal health of mice. It was concluded that naringin can significantly ameliorate the pathogenic symptoms of UC through inhibiting inflammatory response and regulating intestinal microbiota, which might be a promising natural therapeutic agent for the dietary treatment of UC and the improvement of intestinal symbiosis.


Assuntos
Colite Ulcerativa/tratamento farmacológico , Sulfato de Dextrana/antagonistas & inibidores , Flavanonas/farmacologia , Microbioma Gastrointestinal/efeitos dos fármacos , Substâncias Protetoras/farmacologia , Animais , Colite Ulcerativa/induzido quimicamente , Modelos Animais de Doenças , Masculino , Camundongos , Camundongos Endogâmicos C57BL , Proteínas de Junções Íntimas/metabolismo
2.
Br J Pharmacol ; 175(19): 3797-3812, 2018 10.
Artigo em Inglês | MEDLINE | ID: mdl-30007036

RESUMO

BACKGROUND AND PURPOSE: Calprotectin is a heterodimer composed of two myeloid-related proteins, S100A8 and S100A9, that is abundant in neutrophils and monocytes/macrophages. Faecal levels of calprotectin are used routinely to monitor inflammatory bowel disease activity. EXPERIMENTAL APPROACH: We aimed to assess the role of calprotectin in intestinal inflammation, using the dextran sulfate sodium model of colitis in mice. Calprotectin was administered (50 or 100 µg·day-1 ) by the intrarectal or by i.p. injection (50 µg·day-1 only). The condition of the mice was characterized by morphological and biochemical methods. KEY RESULTS: Intrarectal calprotectin protected significantly against colitis, as shown by lower levels of macroscopic and microscopic damage, colonic myeloperoxidase activity and decreased expression of TNFα and toll-like receptor 4. IL-17 production by spleen and mesenteric lymph node cells was reduced. Calprotectin had no effect on body weight loss or colonic thickening. There were no effects of calprotectin after i.p. injection. Calprotectin had virtually no effects in control, non-colitic mice. Calprotectin had almost no effect on the colonic microbiota but enhanced barrier function. Treatment of rat IEC18 intestinal epithelial cells in vitro with calprotectin induced output of the chemokines CXL1 and CCL2, involving the receptor for advanced glycation end products- and NFκB. CONCLUSION AND IMPLICATIONS: Calprotectin exerted protective effects in experimental colitis when given by the intrarectal route, by actions that appear to involve effects on the epithelium.


Assuntos
Colite/prevenção & controle , Inflamação/prevenção & controle , Complexo Antígeno L1 Leucocitário/farmacologia , Administração Retal , Animais , Células Cultivadas , Colite/induzido quimicamente , Colite/tratamento farmacológico , Colite/patologia , Sulfato de Dextrana/antagonistas & inibidores , Modelos Animais de Doenças , Feminino , Inflamação/induzido quimicamente , Inflamação/tratamento farmacológico , Inflamação/patologia , Complexo Antígeno L1 Leucocitário/administração & dosagem , Camundongos , Camundongos Endogâmicos C57BL
3.
Br J Pharmacol ; 175(17): 3563-3580, 2018 09.
Artigo em Inglês | MEDLINE | ID: mdl-29945292

RESUMO

BACKGROUND AND PURPOSE: Activation of the human pregnane X receptor (PXR; NR1I2) has potential therapeutic uses for inflammatory bowel disease (IBD). Imperatorin (IMP), a naturally occurring coumarin, is the main bioactive ingredient of Angelica dahurica Radix, which is regularly used to treat the common cold and intestinal disorders. However, there are no data on the protective effects of IMP against IBD. EXPERIMENTAL APPROACH: The effects of IMP on PXR-modulated cytochrome P450 3A4 (CYP3A4) expression were assessed using a PXR transactivation assay, a mammalian two-hybrid assay, a competitive ligand-binding assay, analysis of CYP3A4 mRNA and protein expression levels and measurement of CYP3A4 activity using a cell-based reporter gene assay and in vitro model. The inhibitory effects of IMP on NF-κB activity were evaluated by a reporter assay and NF-κB p65 nuclear translocation. The anti-IBD effects of IMP were investigated in a dextran sulphate sodium (DSS)-induced colitis mouse model. Colon inflammatory cytokines were assessed by elisa. KEY RESULTS: IMP activated CYP3A4 promoter activity, recruited steroid receptor coactivator 1 to the ligand-binding domain of PXR and increased the expression and activity of CYP3A4. PXR knockdown substantially reduced IMP-induced increase in CYP3A4 expression. Furthermore, IMP-mediated PXR activation suppressed the nuclear translocation of NF-κB and down-regulated LPS-induced expression of pro-inflammatory genes. Nevertheless, PXR knockdown partially reduced the IMP-mediated inhibition of NF-κB. IMP ameliorated DSS-induced colitis by PXR/NF-κB signalling. CONCLUSIONS AND IMPLICATIONS: IMP acts as a PXR agonist to attenuate DSS-induced colitis by suppression of the NF-κB-mediated pro-inflammatory response in a PXR/NF-κB-dependent manner.


Assuntos
Colite/induzido quimicamente , Colite/prevenção & controle , Sulfato de Dextrana/antagonistas & inibidores , Sulfato de Dextrana/toxicidade , Furocumarinas/farmacologia , Receptor de Pregnano X/agonistas , Animais , Linhagem Celular Tumoral , Humanos , Masculino , Camundongos , Camundongos Endogâmicos C57BL
4.
J Microbiol Methods ; 144: 1-7, 2018 01.
Artigo em Inglês | MEDLINE | ID: mdl-29107603

RESUMO

The Dextran Sulfate Sodium (DSS) induced colitis mouse model is commonly used to investigate human inflammatory bowel disease (IBD). Nucleic acid extracts originating from these animals are often contaminated with DSS, which is a strong inhibitor of many enzymatic based molecular biology reactions including PCR and reverse-transcription (RT). Methods for removing DSS from nucleic acids extracts exist for RNA, but no effective protocol for DNA or cDNA is currently available. However, spermine has previously been shown to be an effective agent for counteracting DSS inhibition of polynucleotide kinase, which led to the hypothesis, that spermine could be used to counteract DSS inhibition of PCR and RT. We investigated the means of adding spermine in an adequate concentration to PCR based protocols (including qPCR, two-step RT-qPCR, and amplicon sequencing library preparation) to remove DSS inhibition. Within the range up to 0.01g/L, spermine can be added to PCR/qPCR or RT prophylactically without a significant reduction of reaction efficiency. Addition of spermine at the concentration of 0.08g/L can be used to recover qualitative PCR signal inhibited by DSS in concentrations up to 0.32g/L. For optimal quantitative analysis, the concentration of spermine requires fine adjustment. Hence, we present here a simple fluorometric based method for adjusting the concentration of spermine ensuring an optimal efficiency of the reaction exposed to an unknown concentration of DSS. In conclusion, we demonstrate a cost effective and easy method to counteract DSS inhibition in PCR and two-step RT-qPCR. Fixed or fine-tuned concentrations of spermine can be administered depending on the qualitative or quantitative character of the analysis.


Assuntos
Sulfato de Dextrana/antagonistas & inibidores , Reação em Cadeia da Polimerase/métodos , Reação em Cadeia da Polimerase Via Transcriptase Reversa/métodos , Espermina/química , Animais , DNA/análise , DNA/isolamento & purificação , Sulfato de Dextrana/química , Modelos Animais de Doenças , Humanos , Camundongos , Reação em Cadeia da Polimerase/normas , Polinucleotídeo 5'-Hidroxiquinase/efeitos dos fármacos , RNA/análise , RNA/isolamento & purificação , RNA Ribossômico 16S/genética , Reação em Cadeia da Polimerase Via Transcriptase Reversa/normas , Fatores de Tempo
5.
Antiviral Res ; 143: 186-194, 2017 07.
Artigo em Inglês | MEDLINE | ID: mdl-28457855

RESUMO

Zika virus (ZIKV) is an arthropod-borne flavivirus that causes newborn microcephaly and Guillian-Barré syndrome in adults. No therapeutics are available to treat ZIKV infection or other flaviviruses. In this study, we explored the inhibitory effect of glycosaminoglycans and analogues against ZIKV infection. Highly sulfated heparin, dextran sulfate and suramin significantly inhibited ZIKV infection in Vero cells. De-sulfated heparin analogues lose inhibitory effect, implying that sulfonate groups are critical for viral inhibition. Suramin, an FDA-approved anti-parasitic drug, inhibits ZIKV infection with 3-5 log10 PFU viral reduction with IC50 value of ∼2.5-5 µg/ml (1.93 µM-3.85 µM). A time-of-drug-addition study revealed that suramin remains potent even when administrated at 1-24 hpi. Suramin inhibits ZIKV infection by preventing viral adsorption, entry and replication. Molecular dynamics simulation revealed stronger interaction of suramin with ZIKV NS3 helicase than with the envelope protein. Suramin warrants further investigation as a potential antiviral candidate for ZIKV infection. Heparan sulfate (HS) is a cellular attachment receptor for multiple flaviviruses. However, no direct ZIKV-heparin interaction was observed in heparin-binding analysis, and downregulate or removal of cellular HS with sodium chlorate or heparinase I/III did not inhibit ZIKV infection. This indicates that cell surface HS is not utilized by ZIKV as an attachment receptor.


Assuntos
Suramina/antagonistas & inibidores , Infecção por Zika virus/prevenção & controle , Zika virus/efeitos dos fármacos , Animais , Anticorpos Antivirais , Cloratos/farmacologia , Chlorocebus aethiops , DNA Helicases/metabolismo , Sulfato de Dextrana/antagonistas & inibidores , Flavivirus/efeitos dos fármacos , Glicosaminoglicanos/farmacologia , Heparina/análogos & derivados , Heparina/química , Heparina/farmacologia , Heparitina Sulfato/farmacologia , Concentração Inibidora 50 , Camundongos , Simulação de Acoplamento Molecular , Simulação de Dinâmica Molecular , RNA Helicases/química , RNA Helicases/efeitos dos fármacos , Serina Endopeptidases/química , Serina Endopeptidases/efeitos dos fármacos , Suramina/administração & dosagem , Células Vero , Proteínas do Envelope Viral/metabolismo , Proteínas não Estruturais Virais/química , Proteínas não Estruturais Virais/efeitos dos fármacos , Internalização do Vírus/efeitos dos fármacos , Replicação Viral/efeitos dos fármacos , Zika virus/fisiologia , Infecção por Zika virus/virologia
6.
Drug Des Devel Ther ; 9: 6343-62, 2015.
Artigo em Inglês | MEDLINE | ID: mdl-26674743

RESUMO

Tanshinone IIA (Tan IIA) (C19H18O3) is one of the major active lipophilic components in a conventional Chinese medicine called danshen, and it has long been used in the People's Republic of China and other neighboring countries to treat patients suffering from inflammatory bowel disease (IBD). Previous experiments by many teams determined which mechanism of Tan IIA is relevant to the treatment of IBD associated with inflammation and the pregnane X receptor (PXR). The current study demonstrated that Tan IIA is an efficacious PXR agonist and its ability to induce CYP3A4 mRNA and protein expression was mediated by the transactivation of PXR, a known target of abrogating inflammation in IBD. Clinical symptoms in mice and histological assessment data suggested that administration of Tan IIA in mice demonstrated significant protection and showed that in DSS-induced IBD it acts in a concentration-dependent manner. PXR-silenced mice treated with Tan IIA demonstrated low protection against DSS-induced mouse IBD and exacerbated the severity of IBD compared with wild-type mice; PXR-silenced mice demonstrated the necessity for PXR in Tan IIA-mediated upregulation of xenobiotic metabolism genes. The IBD treatment effects of Tan IIA are partially due to PXR-mediated upregulation of xenobiotic metabolism and downregulation of inflammatory mediators. The novel findings reported here may contribute to the effective utilization of Tan IIA and its derivatives as a PXR ligand in the treatment of human IBD. This suggests that Tan IIA may have considerable clinical utility.


Assuntos
Abietanos/farmacologia , Sulfato de Dextrana/antagonistas & inibidores , Doenças Inflamatórias Intestinais/induzido quimicamente , Doenças Inflamatórias Intestinais/tratamento farmacológico , Receptores de Esteroides/agonistas , Animais , Colite/induzido quimicamente , Colite/tratamento farmacológico , Citocromo P-450 CYP3A/genética , Citocromo P-450 CYP3A/metabolismo , Relação Dose-Resposta a Droga , Células Hep G2 , Humanos , Masculino , Camundongos , Camundongos Endogâmicos BALB C , Receptor de Pregnano X , RNA Mensageiro/genética , Receptores de Esteroides/metabolismo , Relação Estrutura-Atividade , Células Tumorais Cultivadas
7.
Food Chem Toxicol ; 47(6): 1311-7, 2009 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-19285535

RESUMO

We have addressed in this study the possible protective role of the main principle of turmeric pigment; curcumin on a murine model of ulcerative colitis (UC). Colitis was induced by administration of dextran sulfate sodium (DSS) (3% W/V) in drinking water to male Swiss albino rats for 5 consecutive days. DSS challenge induced UC model that was well characterized morphologically and biochemically. DSS produced shrinkage of colon length and increased the relative colon weight/length ratio accompanied by mucosal edema and bloody stool. Histologically, DSS produced submucosal erosions, ulceration, inflammatory cell infiltration and crypt abscess as well as epithelioglandular hyperplasia. The model was confirmed biochemically, and the test battery entailed elevated serum tumor necrosis factor (TNF-alpha) and colonic activity of myleoperoxidase (MPO). Colonic glutathione-S-transferase (GST) activity and its substrate concentration; GSH, were notably reduced, while lipid peroxidation, expressed as malondialdehyde (MDA) level, and total nitric oxide (NO) were significantly increased. Prior administration of curcumin (100mg/kg, IP) for 7 consecutive days ahead of DSS challenge mitigated the injurious effects of DSS and ameliorated all the altered biochemical parameters. These results suggest that curcumin could possibly have a protective role in ulcerative colitis probably via regulation of oxidant/anti-oxidant balance and modulation of the release of some inflammatory endocoids, namely TNF-alpha and NO.


Assuntos
Anti-Inflamatórios não Esteroides/uso terapêutico , Colite Ulcerativa/induzido quimicamente , Colite Ulcerativa/prevenção & controle , Curcumina/uso terapêutico , Sulfato de Dextrana/antagonistas & inibidores , Sulfato de Dextrana/toxicidade , Animais , Colite Ulcerativa/patologia , Colo/enzimologia , Glutationa/metabolismo , Glutationa Transferase/metabolismo , Mucosa Intestinal/patologia , Peroxidação de Lipídeos/efeitos dos fármacos , Masculino , Malondialdeído/metabolismo , Camundongos , Óxido Nítrico/metabolismo , Peroxidase/metabolismo , Ratos , Fator de Necrose Tumoral alfa/metabolismo
8.
Adv Exp Med Biol ; 643: 265-71, 2009.
Artigo em Inglês | MEDLINE | ID: mdl-19239157

RESUMO

Effects of dietary taurine on the experimental colitis induced by dextran sulfate sodium (DSS) were studied. C57BL/6 mice administrated taurine or placebo for 5 days were given 3% DSS to induce acute. The colitis was as-sessed using indices such as diarrhea/bleeding scores, colon length change, histological score and tissue myeloperoxidase (MPO) activity. Further, tissue mRNA levels of interleukin (IL)-1beta, tumor necrosis factor (TNF)-alpha and macrophage inflammatory protein (MIP)-2, were determined by real-time PCR. Taurine supplementation significantly attenuated the severity of diarrhea, colon shortening, histological score, MPO activity elevation and abnormal MIP-2 gene expression, indicating that taurine prevents DSS-induced colitis. Taurine also inhibited the TNF-alpha-induced secretion of IL-8 (a human homologue of MIP-2) from human intestinal epithelial Caco-2 cells. Inhibition of chemokine secretion from intestinal cells may be involved in the mechanisms underlying the cytoprotective function of taurine in the intestinal epithelium.


Assuntos
Sulfato de Dextrana/antagonistas & inibidores , Dieta , Doenças Inflamatórias Intestinais/prevenção & controle , Taurina/farmacologia , Animais , Sulfato de Dextrana/toxicidade , Modelos Animais de Doenças , Doenças Inflamatórias Intestinais/induzido quimicamente , Doenças Inflamatórias Intestinais/enzimologia , Interleucina-8/metabolismo , Mucosa Intestinal/efeitos dos fármacos , Mucosa Intestinal/metabolismo , Camundongos , Peroxidase/metabolismo , Taurina/administração & dosagem
9.
Int J Mol Med ; 17(2): 331-4, 2006 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-16391834

RESUMO

Recent studies have suggested that the enhanced release of reactive oxygen species (ROS) plays an important role in the pathogenesis of clinical inflammatory bowel disease (IBD), such as ulcerative colitis and Crohn's disease. In the present study, we investigated the effects of the free radical scavengers edaravone and tempol in the development of experimental dextran sulfate sodium (DSS)-induced colitis in mice. Male BALB/cA mice were fed 4% (w/w of diet) DSS in standard powder chow for 8 days. Edaravone, tempol, or vehicle saline were then injected subcutaneously twice per day. After the experimental period, the colonic length, histological damage score, and mucosal myeloperoxidase (MPO) and serum interleukin-6 (IL-6) levels were measured. Edaravone (15 mg/kg/day) and tempol (5-15 mg/kg/day) suppressed the colonic shortening and the damage score. In particular, tempol at 15 mg/kg/day significantly attenuated the colonic shortening and damage score. Edaravone and tempol suppressed the serum IL-6 levels, and significantly suppressed the increased colonic MPO levels. These results strongly support the involvement of ROS in the pathogenesis of DSS-induced colitis. A clinical effect for edaravone and tempol in IBD patients is strongly expected.


Assuntos
Antipirina/análogos & derivados , Colite/induzido quimicamente , Colite/prevenção & controle , Óxidos N-Cíclicos/farmacologia , Sulfato de Dextrana/antagonistas & inibidores , Sequestradores de Radicais Livres/farmacologia , Animais , Antipirina/farmacologia , Colite/sangue , Colite/patologia , Sulfato de Dextrana/farmacologia , Modelos Animais de Doenças , Edaravone , Interleucina-6/sangue , Masculino , Camundongos , Camundongos Endogâmicos BALB C , Peroxidase/sangue , Marcadores de Spin
10.
Biosci Biotechnol Biochem ; 68(2): 436-9, 2004 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-14981311

RESUMO

Interleukin (IL)-1beta, an anti-apoptotic and pro-inflammatory cytokine, plays an important role in the onset of inflammation-associated disease. We examined the suppressive effects of a total of 39 synthetic or natural compounds on dextran sulfate sodium-induced IL-1beta production in murine peritoneal macrophages. Several compounds, including alpha-tocopherol, gallic acid, (-)-catechin and rutin, were found to be highly effective for attenuating IL-1beta production, suggesting that they would be useful for anti-inflammatory application.


Assuntos
Fatores Biológicos/farmacologia , Sulfato de Dextrana/antagonistas & inibidores , Sulfato de Dextrana/farmacologia , Interleucina-1/metabolismo , Macrófagos Peritoneais/metabolismo , Animais , Anti-Inflamatórios/farmacologia , Antioxidantes/farmacologia , Inibidores de Ciclo-Oxigenase/farmacologia , Avaliação Pré-Clínica de Medicamentos , Inibidores Enzimáticos/farmacologia , Feminino , Técnicas In Vitro , Macrófagos Peritoneais/efeitos dos fármacos , Camundongos , Camundongos Endogâmicos ICR , Óxido Nítrico Sintase/antagonistas & inibidores , Óxido Nítrico Sintase Tipo II
11.
Int Immunopharmacol ; 3(13-14): 1731-41, 2003 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-14636824

RESUMO

In this study, we have evaluated the efficacy of dosmalfate, a new flavonoid derivative compound, for the prevention and treatment of experimental colitis. To induce colitis, BALB/c mice received 5% dextran sulphate sodium (DSS) in their drinking water continuously for 7 days. Colitis was quantified by a clinical damage score, colon length, weight loss, stool consistency and rectal bleeding. Inflammatory response was assessed by neutrophil infiltration, determined by histology and myeloperoxidase (MPO) activity. Interleukin (IL)-1 beta, prostaglandins (PG)E(2) and (PG)D(2) concentrations in colonic tissue, histological and histochemical analysis of the lesions were also measured. Dosmalfate (400-800 mg/kg body weight, p.o.) ameliorated severe colitis reduced the degree of inflammation through reduction of neutrophil infiltration and IL-1 beta levels. (PG)E(2) and (PG)D(2) synthesis were significantly reduced in colitis control group and treatment with dosmalfate abolished the decrease in PG synthesis in colon mucosa. We conclude that dosmalfate is protective in acute DSS-induced colitis. The beneficial effects seem to be related to a decrease of neutrophil infiltration, absence of up-regulation of IL-1 beta and increase of PG production in colon mucosa.


Assuntos
Colite Ulcerativa/induzido quimicamente , Sulfato de Dextrana/efeitos adversos , Sulfato de Dextrana/antagonistas & inibidores , Diosmina/análogos & derivados , Diosmina/uso terapêutico , Administração Oral , Animais , Colite Ulcerativa/tratamento farmacológico , Colo Descendente/efeitos dos fármacos , Colo Descendente/lesões , Colo Descendente/ultraestrutura , Colo Transverso/efeitos dos fármacos , Colo Transverso/lesões , Colo Transverso/ultraestrutura , Sulfato de Dextrana/administração & dosagem , Dinoprostona/biossíntese , Diosmina/administração & dosagem , Diosmina/farmacocinética , Modelos Animais de Doenças , Ingestão de Líquidos , Flavonoides/administração & dosagem , Flavonoides/química , Flavonoides/farmacocinética , Interleucina-1/biossíntese , Mucosa Intestinal/efeitos dos fármacos , Mucosa Intestinal/enzimologia , Mucosa Intestinal/lesões , Masculino , Camundongos , Camundongos Endogâmicos BALB C , Infiltração de Neutrófilos/efeitos dos fármacos , Peroxidase/metabolismo , Prostaglandina D2/biossíntese , Fatores de Tempo , Água
12.
Am J Physiol Gastrointest Liver Physiol ; 285(6): G1259-67, 2003 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-12893626

RESUMO

Ileal pouch-anal anastomosis (IPAA) is an excellent surgical option for patients with chronic ulcerative colitis (CUC) requiring colectomy; however, persistent episodes of ileal pouch inflammation, or pouchitis, may result in debilitating postoperative complications. Because considerable evidence implicates substance P (SP) as an inflammatory mediator of CUC, we investigated whether SP participates in the pathophysiology of pouchitis. With the use of a rat model of IPAA that we developed, we showed that ileal pouch MPO levels and neurokinin 1 receptor (NK-1R) protein expression by Western blot analysis were significantly elevated 28 days after IPAA surgery. In situ hybridization and immunohistochemistry showed that the increase in NK-1R protein expression was localized to the lamina propria and epithelia of pouch ileum. The intraperitoneal administration of the NK-1R antagonist (NK-1RA) CJ-12,255 for 4 days, starting on day 28, was effective in reducing MPO levels. Starting on day 28, animals with IPAA were given 5% dextran sulfate sodium (DSS) in their drinking water for 4 days, which caused histological and physical signs of clinical pouchitis concomitant with significant increases in ileal pouch MPO concentrations as well as NK-1R protein expression by Western blot analysis. In situ hybridization and immunohistochemistry showed that the increase in NK-1R protein expression was especially evident in crypt epithelia of pouch ileum. When the NK-1RA was administered 1 day before starting DSS and continued for the duration of DSS administration, the physical signs of clinical pouchitis and the rise in MPO were prevented. These data implicate SP in the pathophysiology of pouchitis and suggest that NK-1RA may be of therapeutic value in the management of clinical pouchitis.


Assuntos
Sulfato de Dextrana/antagonistas & inibidores , Sulfato de Dextrana/farmacologia , Antagonistas dos Receptores de Neurocinina-1 , Pouchite/patologia , Animais , Compostos Bicíclicos Heterocíclicos com Pontes/farmacologia , Imuno-Histoquímica , Hibridização In Situ , Mucosa Intestinal/efeitos dos fármacos , Mucosa Intestinal/patologia , Masculino , Ratos , Ratos Sprague-Dawley , Receptores da Neurocinina-1/metabolismo
13.
J Interferon Cytokine Res ; 23(4): 193-201, 2003 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-12856331

RESUMO

The use of biologics has promising potential in the treatment of inflammation. Studies with cultured cells and mouse models of disease have ascribed proinflammatory and anti-inflammatory functions to oncostatin M (OSM) and the related cytokine, interleukin-6 (IL-6). Here, we examined the effect of systemic administration of adenoviral (Ad) vectors encoding either murine OSM (AdMuOSM) or murine IL-6 (AdMuIL-6) in a mouse model of colitis. BALB/c mice were treated with a 5-day course of 4% dextran-sodium sulfate (DSS) water with or without administration of adenoviral vectors (i.p. or i.m. at 10(7) plaque-forming units [pfu]) given as a cotreatment or therapy. The deletion variant of the adenovirus served as a control for adenoviral infection. Colitis was assessed by (1) morphology (damage score, macrophage infiltration, apoptosis) and (2) function (myeloperoxidase activity and Ussing chamber analysis of epithelial ion transport). Infection with adenovirus alone did not affect colonic form or function. AdMuOSM (either i.p. or i.m.) significantly reduced the severity of the DSS-induced colitis. There was less damage, reduced macrophage infiltration, fewer apoptotic bodies, and a significant improvement in stimulated ion transport in colonic tissues from the treated mice. No benefit of AdMuIL-6 treatment was observed in this model system. Thus, systemic administration of AdMuOSM given as a cotreatment and to a lesser extent as a therapy was found to be of benefit in DSS-induced colitis, a murine model of inflammatory bowel disease (IBD).


Assuntos
Adenoviridae/genética , Colite/induzido quimicamente , Colite/prevenção & controle , Sulfato de Dextrana/toxicidade , Peptídeos/genética , Proteínas de Fase Aguda/metabolismo , Animais , Colo/efeitos dos fármacos , Colo/patologia , Sulfato de Dextrana/antagonistas & inibidores , Vetores Genéticos , Humanos , Masculino , Camundongos , Camundongos Endogâmicos BALB C , Oncostatina M , Peptídeos/metabolismo , Proteínas Recombinantes/metabolismo , Transfecção/métodos
14.
Jpn J Cancer Res ; 92(4): 396-403, 2001 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-11346461

RESUMO

The biological roles of peroxisome proliferator-activated receptors (PPARs) in various diseases, including inflammation and cancer, have been highlighted recently. Although PPARgamma ligand is suspected to play an important role in carcinogenesis, its effects on colon tumorigenesis remain undetermined. The present time-course study was conducted to investigate possible modifying effects of a PPARgamma ligand, troglitazone, on the development and growth of aberrant crypt foci (ACF), putative precursor lesions for colon carcinoma, induced by azoxymethane (AOM) or dextran sodium sulfate (DSS) in male F344 rats. Oral troglitazone (10 or 30 mg / kg body weight (b.w.)) significantly reduced AOM (two weekly subcutaneous injections, 20 mg / kg b.w.)-induced ACF. Treatment with troglitazone increased apoptosis and decreased polyamine content and ornithine decarboxylase (ODC) activity in the colonic mucosa of rats treated with AOM. Gastric gavage of troglitazone also inhibited colitis and ACF induced by DSS (1% in drinking water), in conjunction with increased apoptosis and reduced colonic mucosal polyamine level and ODC activity. Our results suggest that troglitazone, a synthetic PPARgamma ligand, can inhibit the early stage of colon tumorigenesis with or without colitis.


Assuntos
Antineoplásicos/farmacologia , Azoximetano/análogos & derivados , Cromanos/farmacologia , Colite/prevenção & controle , Neoplasias do Colo/prevenção & controle , Lesões Pré-Cancerosas/prevenção & controle , Receptores Citoplasmáticos e Nucleares/metabolismo , Tiazóis/farmacologia , Tiazolidinedionas , Fatores de Transcrição/metabolismo , Animais , Apoptose/efeitos dos fármacos , Azoximetano/antagonistas & inibidores , Poliaminas Biogênicas/metabolismo , Carcinógenos/antagonistas & inibidores , Colite/induzido quimicamente , Colite/metabolismo , Neoplasias do Colo/induzido quimicamente , Neoplasias do Colo/metabolismo , Sulfato de Dextrana/antagonistas & inibidores , Mucosa Intestinal/efeitos dos fármacos , Mucosa Intestinal/enzimologia , Mucosa Intestinal/metabolismo , Ligantes , Masculino , Ornitina Descarboxilase/metabolismo , Lesões Pré-Cancerosas/induzido quimicamente , Lesões Pré-Cancerosas/metabolismo , Ratos , Ratos Endogâmicos F344 , Troglitazona
15.
Cancer Res ; 61(6): 2424-8, 2001 Mar 15.
Artigo em Inglês | MEDLINE | ID: mdl-11289109

RESUMO

The biological role of the peroxisome proliferator-activated receptors (PPARs) in various diseases, including inflammation and cancer, has been highlighted recently. Although PPARgamma ligands have been found to inhibit mammary carcinogenesis in rodents, the effects on colon tumorigenesis are controversial. In the present study, three different experiments were conducted to investigate the modifying effects of PPARs ligands (PPARalpha and PPARgamma) on colitis and an early phase of colitis-related colon carcinogenesis in male F344 rats. In the first experiment, gastric gavage of troglitazone (PPARgamma ligand, 10 or 100 mg/kg body weight) or bezafibrate (PPARalpha ligand, 10 or 100 mg/kg body weight) inhibited colitis induced by dextran sodium sulfate (DSS) and lowered trefoil factor-2 content in colonic mucosa. In the second experiment, dietary administration (0.01 or 0.05% in diet) of troglitazone and bezafibrate for 4 weeks significantly reduced azoxymethane (AOM, two weekly s.c. injections, 20 mg/kg body weight)-induced formation of aberrant crypts foci, which are precursor lesions for colon carcinoma. In the third experiment, dietary administration (0.01% in diet for 6 weeks) of pioglitazone (PPARgamma ligand), troglitazone, and bezafibrate effectively suppressed DSS/AOM-induced ACF. Administration of both ligands significantly reduced cell proliferation activity in colonic mucosa exposed to DSS and AOM. Our results suggest that synthetic PPARs ligands (PPARalpha and PPARgamma) can inhibit the early stages of colon tumorigenesis with or without colitis.


Assuntos
Anticarcinógenos/farmacologia , Bezafibrato/farmacologia , Cromanos/farmacologia , Colite/prevenção & controle , Neoplasias do Colo/prevenção & controle , Mucinas , Proteínas Musculares , Neuropeptídeos , Lesões Pré-Cancerosas/prevenção & controle , Receptores Citoplasmáticos e Nucleares/metabolismo , Tiazóis/farmacologia , Tiazolidinedionas , Fatores de Transcrição/metabolismo , Animais , Azoximetano/antagonistas & inibidores , Azoximetano/toxicidade , Divisão Celular/efeitos dos fármacos , Colite/induzido quimicamente , Colite/metabolismo , Neoplasias do Colo/induzido quimicamente , Sulfato de Dextrana/antagonistas & inibidores , Sulfato de Dextrana/toxicidade , Substâncias de Crescimento/metabolismo , Mucosa Intestinal/citologia , Mucosa Intestinal/efeitos dos fármacos , Mucosa Intestinal/metabolismo , Ligantes , Masculino , Região Organizadora do Nucléolo/efeitos dos fármacos , Região Organizadora do Nucléolo/metabolismo , Peptídeos/metabolismo , Lesões Pré-Cancerosas/induzido quimicamente , Proteínas/metabolismo , Ratos , Ratos Endogâmicos F344 , Coloração pela Prata , Fator Trefoil-2 , Fator Trefoil-3 , Troglitazona
16.
JPEN J Parenter Enteral Nutr ; 23(5 Suppl): S70-3, 1999.
Artigo em Inglês | MEDLINE | ID: mdl-10483900

RESUMO

BACKGROUND: We investigated the effects of pectin, a soluble dietary fiber, on the morphological parameters of the small intestine. In addition, we tested the effects of butyrate enemas on dextran sulfate sodium (DSS)-induced experimental colitis. METHODS: Male Wistar rats were fed an elemental diet containing 2.5% pectin for 14 days, and several parameters were then determined. DSS-induced colitis was evoked by the oral administration of water containing 3% DSS for 10 days. The butyrate enema (3 mL of 100 mmol/L butyrate per day) was begun 7 days before the DSS treatment. Interleukin (IL)-8 secretion in the human intestinal epithelial cell line HT-29 was determined by enzyme-linked immunosorbent assay (ELISA). RESULTS: Pectin feeding induced a significant increase in the villus height and crypt depth in the small intestine. These effects correlated with a significant increase in plasma enteroglucagon levels. Pretreatment with a butyrate enema significantly blocked the development of DSS-induced experimental colitis. In the in vitro experiment, sodium butyrate dose-dependently inhibited tumor necrosis factor (TNF)-alpha-induced IL-8 secretion in HT-29 cells. CONCLUSIONS: A trophic effect due to dietary fiber was directly observed. The generation of short-chain fatty acids and the induction of enteroglucagon release might play an important role in this process. Butyrate, one of the major metabolites of dietary fiber, exerted a potent anti-inflammatory effect both in vivo and in vitro. Dietary fiber may therefore play important roles in the regulation of normal and pathological conditions in the intestine.


Assuntos
Anti-Inflamatórios/uso terapêutico , Anticoagulantes/uso terapêutico , Antidiarreicos/uso terapêutico , Butiratos/uso terapêutico , Colite/tratamento farmacológico , Fibras na Dieta/uso terapêutico , Pectinas/uso terapêutico , Adenocarcinoma/tratamento farmacológico , Adenocarcinoma/metabolismo , Animais , Anti-Inflamatórios/administração & dosagem , Anticoagulantes/administração & dosagem , Anticoagulantes/antagonistas & inibidores , Antidiarreicos/administração & dosagem , Butiratos/administração & dosagem , Colite/induzido quimicamente , Colite/enzimologia , Sulfato de Dextrana/antagonistas & inibidores , Sulfato de Dextrana/toxicidade , Enema , Humanos , Interleucina-8/metabolismo , Intestino Delgado/efeitos dos fármacos , Intestino Delgado/metabolismo , Masculino , Pectinas/administração & dosagem , Peroxidase/metabolismo , Ratos , Ratos Wistar , Células Tumorais Cultivadas/efeitos dos fármacos , Células Tumorais Cultivadas/metabolismo , Fator de Necrose Tumoral alfa/farmacologia
17.
Clin Exp Immunol ; 117(3): 462-8, 1999 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-10469048

RESUMO

We examined the effect of intracolonic administration of anti-adhesion molecule antibodies on DSS-induced colitis in mice. Immunohistochemical staining in mice with colitis showed increased expression of ELAM-1 and ICAM-1 on endothelial cells of vessels in the lamina propria and submucosa at sites of inflamed lesions. Intracolonic administration of anti-ELAM-1 or anti-ICAM-1 antibody decreased bloody stools, anaemia, and histologically evident damage, as well as myeloperoxidase activity and IL-1beta content. We concluded that adhesion molecule expression is important in the development of DSS-induced colitis in mice and that intracolonic administration of anti-adhesion molecule antibodies, especially anti-ELAM-1 antibody, effectively inhibits the colonic inflammation. Intracolonic administration of anti-adhesion molecule antibodies may show therapeutic promise in ulcerative colitis.


Assuntos
Anticorpos Monoclonais/imunologia , Colite Ulcerativa/imunologia , Selectina E/imunologia , Molécula 1 de Adesão Intercelular/imunologia , Animais , Anticorpos Monoclonais/uso terapêutico , Colite Ulcerativa/induzido quimicamente , Colite Ulcerativa/patologia , Colite Ulcerativa/terapia , Sulfato de Dextrana/antagonistas & inibidores , Sulfato de Dextrana/farmacologia , Modelos Animais de Doenças , Relação Dose-Resposta a Droga , Selectina E/biossíntese , Feminino , Imunoterapia , Molécula 1 de Adesão Intercelular/biossíntese , Interleucina-1/análise , Camundongos , Camundongos Endogâmicos BALB C , Peroxidase/metabolismo
18.
Gastroenterology ; 115(4): 874-82, 1998 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-9753490

RESUMO

BACKGROUND & AIMS: Although dextran sodium sulfate (DSS)-induced colitis is a commonly used model of colonic injury, the mechanism of this model is not understood. The aim of this study was to determine the contribution of prostaglandins to the mechanism of DSS-induced epithelial injury. METHODS: Mice were treated with 3% DSS in the drinking water for 5 days followed by water only (recovery). Tissue prostaglandin E2 (PGE2) levels were measured, proliferating cells per cecal crypt were determined by bromodeoxyuridine labeling, and the cellular localization of cyclooxygenase (COX)-1 and COX-2 was determined by immunohistochemistry. RESULTS: DSS decreased the number of proliferating epithelial cells per crypt by approximately 90% and decreased the height of cecal crypts by 40%. Administration of dimethyl PGE2 with DSS reversed the effect of DSS on proliferation but not its effect on crypt shortening. COX-1 was expressed in the crypt epithelium and lamina propria mononuclear cells; DSS treatment down-regulated COX-1 expression only in the epithelium. Dimethyl PGE2 reversed the effect of DSS on COX-1 expression. Recovery was associated with a return to normal COX-1 expression in the epithelium. COX-2 was expressed in lamina propria mononuclear cells. CONCLUSIONS: Epithelial cell proliferation in the presence of DSS contains a PGE2-sensitive component.


Assuntos
16,16-Dimetilprostaglandina E2/farmacologia , Ceco/efeitos dos fármacos , Sulfato de Dextrana/farmacologia , Mucosa Intestinal/efeitos dos fármacos , Animais , Bromodesoxiuridina/metabolismo , Ceco/metabolismo , Ceco/patologia , Divisão Celular/efeitos dos fármacos , Ciclo-Oxigenase 1 , Sulfato de Dextrana/antagonistas & inibidores , Feminino , Mucosa Intestinal/metabolismo , Mucosa Intestinal/patologia , Isoenzimas/metabolismo , Proteínas de Membrana , Camundongos , Camundongos Endogâmicos C3H , Prostaglandina-Endoperóxido Sintases/metabolismo
19.
J Pineal Res ; 19(1): 31-9, 1995 Aug.
Artigo em Inglês | MEDLINE | ID: mdl-8609593

RESUMO

Melatonin administration reduces the severity of dextran sodium sulphate (DSS)-induced colitis in mice. After 7 weeks of daily intraperitoneal melatonin administration (150 micrograms/kg), rectal bleeding and occult blood was eliminated in all mice in which colitis was induced by DSS. In addition the frequency and severity of focal lesions in the mucosa was dramatically reduced. Furthermore, weight loss and higher food consumption observed in DSS-treated mice was reversed in DSS-treated mice injected with melatonin. All treated groups exhibited significant alterations in goblet cell distribution as a result of DSS or melatonin administration. Surprisingly, serum melatonin levels were more than 10 times higher in mice that received DSS as compared to controls. The significant improvement in the conditions of melatonin-treated mice might be due to its effect on the smooth muscles of the colon, the blood supply in the mucosa, its capability as an antioxidant and scavenger of free radicals, or its effect on the immune system of the gut. The higher plasma levels of melatonin in DSS-treated mice might be due to a stress-induced increase in the production of gastrointestinal (GIT) melatonin.


Assuntos
Colite/induzido quimicamente , Colite/tratamento farmacológico , Sulfato de Dextrana/antagonistas & inibidores , Sulfato de Dextrana/toxicidade , Melatonina/farmacologia , Animais , Colite/patologia , Feminino , Mucosa Intestinal/efeitos dos fármacos , Mucosa Intestinal/patologia , Masculino , Melatonina/sangue , Camundongos , Antagonistas da Serotonina/farmacologia
20.
Inflammation ; 16(5): 497-507, 1992 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-1428124

RESUMO

Contact of plasma with a negatively charged surface activates prekallikrein and factor XII reciprocally. Activation of prekallikrein by several activators was impaired in bovine plasma when compared to that in human plasma. The activated partial thromboplastin time of bovine plasma, induced by several activators, was significantly longer than that of human plasma. Cleavage of [125I]factor XII was optimum at 10 min in human plasma but took up to 60 min in bovine plasma. Addition of bovine plasma to human plasma caused significant inhibition of dextran sulfate-induced prekallikrein activation, indicating that the impaired rate of contact activation in bovine plasma is due to the presence of inhibitors. The inhibitory effect was greater at lower concentrations of dextran sulfate but could not be abolished by increasing the concentration. The inhibitory activity eluted in two peaks at low and medium salt concentrations on carboxymethyl ion-exchange chromatography of bovine plasma.


Assuntos
Sulfato de Dextrana/antagonistas & inibidores , Plasma/fisiologia , Pré-Calicreína/metabolismo , Animais , Testes de Coagulação Sanguínea , Bovinos , Cromatografia por Troca Iônica , Ativação Enzimática/efeitos dos fármacos , Fator XII/metabolismo , Humanos , Radioisótopos do Iodo
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...